Johnson & Johnson’s single-dose COVID-19 vaccine trial reaches full enrollment
Johnson & Johnson announced it reached full enrollment for its late-stage single-dose coronavirus vaccine trial with about 45,000 participants.
In a company statement, the health care giant said there is a high incidence of the virus circulating among the general populations where the U.S.-based study trials (called Ensemble) are underway, which will allow the company the data it needs. In general, when the rate of illness falls in a population, it can slow the enrollment process.
WHO SHOULD COVID-19 VACCINES GO TO NEXT?
Company officials said interim data, or data released before the trial is over, is expected by the end of January 2021. Though this news lags behind other companies on the COVID-19 vaccine front, like Pfizer and Moderna, officials welcome as many vaccine candidates as possible in order to meet global demand and ultimately conquer the ongoing health crisis.
